𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Mutational analysis of StAR gene in adrenal tumors

✍ Scribed by Antonio Stigliano; Stefania Caiola; Ester Siniscalchi; Enrico Papini; Anna Crescenzi; Salvatore Monti; Giorgio Arnaldi; Franco Mantero; Francesco Sciarra; Vincenzo Toscano


Publisher
John Wiley and Sons
Year
2001
Tongue
French
Weight
187 KB
Volume
97
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Adrenal adenomas and carcinomas are mostly monoclonal, suggesting that a genetic alteration in a progenitor cell may contribute to their development. However, the molecular pathogenesis of these tumors still remains unclear. It has been already excluded that activating mutations of the ACTH receptor or of G protein stimulator alpha sub‐units, affecting cAMP pathway, is involved in the tumorigenesis. Therefore, this work has been focused on post‐transductional (ACTH) signal alterations and in particular on the mutational analysis of the Steroid Acute Regulatory protein (StAR) gene to verify whether somatic mutations or genomic polymorphisms of this gene may be correlated with adrenal tumorigenesis. Tissue DNA was extracted from 40 functional and non‐functional adrenocortical tumors that were removed from patients aged between 17 and 72 years (mean 43 ± 4). Blood DNA was obtained from 24 patients (aged between 26 and 70 years) affected by adrenal tumors and from 100 healthy subjects without radiological and clinical evidence of adrenal masses, aged between 25–35 years (90 Caucasians and 10 Africans). The DNA was used as the template for the amplification of the StAR gene using the polymerase chain reaction. The amplified DNA of each exon of the StAR gene was purified and sequenced in automatic sequenciator. With the exception of exon 5 showing in codon 203 an homozygous missense mutation, the sequence of the other exons of the StAR gene resulted normal in all tumors studied. The same homozygous mutation (Asp203Ala) was observed in the sequence of exon 5 performed on genomic DNA of the 24 affected patients and in the control subjects. The homozigousity of the mutation observed in all patients (either in tissue or blood samples) and in control subjects, independently of their ethnic origin, led us to suggest that the Asp203Ala cannot be considered as mutation or as polymorphism, but that it must be considered as a mistake in the sequence entered in the Genbank, which needs to be modified accordingly. These data, and those up to now reported in the literature, allow us to suggest that mutations of the gene coding for the protein involved in the initial step of the steroidogenesis could not be considered as a possible cause for the development of adrenal tumors. © 2001 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Mutational analysis of the humanMAOA gen
✍ Tivol, Elizabeth A.; Shalish, Christo; Schuback, Deborah E.; Hsu, Yun-Pung; Brea 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 53 KB 👁 2 views

The monoamine oxidases (MAO-A and MAO-B) are the enzymes primarily responsible for the degradation of amine neurotransmitters, such as dopamine, norepinephrine, and serotonin. Wide variations in activity of these isozymes have been reported in control humans. The MAOA and MAOB genes are located next

Expression and mutation analysis of the
✍ Sally L. Dennis; Shehnaaz S.M. Manji; Darryl P. Carrington; Deborah L. Scarcella 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 214 KB

## Abstract The Wilms' tumor 1 gene, __WT1__, encodes a zinc‐finger protein that is implicated in the development of Wilms' tumor. Mutant or aberrantly expressed WT1 isoforms have also been described in desmoplastic small round cell tumor, acute leukemias, mesothelioma, breast tumors and melanoma.

Mutational analysis of the TrkA gene in
✍ George, Daniel J.; Suzuki, Hiroyoshi; Bova, G. Steven; Isaacs, John T. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 629 KB

## Background: Trka, the high affinity, tyrosine kinase receptor for nerve growth factor (ngf) has been implicated as an oncogene in several neoplasms. in prostate cancer, inhibitors of the ngf/trka signal pathway results in tumor growth inhibition. in contrast, inhibition of this trk pathway in th